It takes a village, Nat. Rev. Cancer, vol.15, pp.473-483, 2015. ,
Tumorigenesis: It takes a village, Nat. Rev. Cancer, vol.15, pp.473-483, 2015. ,
Tumour heterogeneity and resistance to cancer therapies, Nat. Rev. Clin. Oncol, vol.15, pp.81-94, 2018. ,
Extracting more information from medical images using advanced feature analysis, Eur. J. Cancer, vol.48, pp.441-446, 2012. ,
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, Nat. Commun, vol.5, 2014. ,
atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer, Nat. Med, vol.24, pp.1852-1858, 2018. ,
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation, Med. Oncol, vol.28, pp.682-688, 2011. ,
Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future, J. Clin. Investig, vol.125, pp.3384-3391, 2015. ,
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers, Drugs Today, vol.53, pp.217-237, 2017. ,
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial, Lancet, vol.387, pp.1837-1846, 2016. ,
Appropriate Use Criteria for 18 F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease, J. Nucl. Med, vol.58, pp.2026-2037, 2017. ,
Imaging with non-FDG PET tracers: Outlook for current clinical applications, Insights Imaging, vol.1, pp.373-385, 2010. ,
Molecular Imaging and Precision Medicine in Breast Cancer, PET Clin, vol.12, pp.39-51, 2017. ,
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: A cost-effectiveness study, Oncotarget, vol.9, 2018. ,
Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer, Clin. Cancer Res, vol.23, pp.407-415, 2017. ,
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy, Clin. Cancer Res, vol.2, pp.933-939, 1996. ,
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications, J. Nucl. Med, vol.57, pp.1269-1275, 2016. ,
PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma, J. Nucl. Med, vol.53, pp.182-190, 2012. ,
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging, J. Nucl. Med, vol.50, pp.974-981, 2009. ,
Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In-or 68Ga-Labeled Affibody Molecules, J. Nucl. Med, vol.51, pp.892-897, 2010. ,
DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer, J. Nucl. Med, vol.54, pp.1869-1875, 2013. ,
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?, Front. Pharmacol, vol.7, p.35, 2016. ,
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial, Ann. Oncol, vol.27, pp.619-624, 2016. ,
HER2 imaging in the ZEPHIR study, Ann. Oncol, vol.27, pp.555-557, 2016. ,
Tumors of the neural crest: Common themes in development and cancer: Tumors of the Neural Crest, Dev. Dyn, vol.244, pp.311-322, 2015. ,
Guidelines on nuclear medicine imaging in neuroblastoma, Eur. J. Nucl. Med. Mol. Imaging, vol.45, 2009. ,
Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients, Am. J. Clin. Oncol, vol.31, pp.271-279, 2008. ,
Diagnostic FDG and FDOPA positron emission tomography scans distinguish the genomic type and treatment outcome of neuroblastoma, Oncotarget, vol.7, pp.18774-18786, 2016. ,
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance, vol.7, pp.1149-1158, 2017. ,
Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms, Contrast Media Mol. Imaging, 2018. ,
A new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma, Nucl. Med. Rev, vol.18, pp.102-106, 2015. ,
Imaging Tumor Phenotype: 1 Plus 1 Is More than 2, J. Nucl. Med, vol.50, pp.1567-1569, 2009. ,
Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms, J. Nucl. Med, vol.60, pp.882-891, 2019. ,
Role of imaging in the staging and response assessment of lymphoma, Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, vol.32, pp.3048-3058, 2014. ,
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy, Blood, vol.128, pp.2489-2496, 2016. ,
Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications, p.20, 2019. ,
Molecular Imaging of Proliferation in Malignant Lymphoma, Cancer Res, vol.66, pp.11055-11061, 2006. ,
Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas, Eur. J. Nucl. Med, vol.25, pp.729-735, 1998. ,
, Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring, vol.280, pp.220-229, 2016.
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL, Oncotarget, vol.5, pp.4050-4059, 2014. ,
18F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients, J. Nucl. Med, vol.59, pp.1380-1385, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02006592
PET of CXCR4 Expression by a 68Ga-Labeled Highly Specific Targeted Contrast Agent, J. Nucl. Med, vol.52, pp.1803-1810, 2011. ,
First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu-and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra-and Extramedullary Disease, J. Nucl. Med, vol.57, pp.248-251, 2016. ,
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors, vol.7, pp.1159-1163, 2017. ,
Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.402-411, 2018. ,
177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma, J. Nucl. Med, vol.52, pp.1041-1047, 2011. ,
Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective, Sci. World J, pp.1-9, 2015. ,
GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors, vol.229, pp.147-167, 2017. ,
Initial Experience with Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients with Refractory Metastatic Neuroblastoma, J. Pediatr. Hematol, vol.38, pp.1-96, 2016. ,
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, N. Engl. J. Med, vol.376, pp.125-135, 2017. ,
Molecular radiotheranostics for neuroendocrine tumours, Clin. Med, vol.17, pp.462-468, 2017. ,
Theranostics of Neuroendocrine Tumors, vol.33, pp.358-366, 2017. ,
Immuno-PET for Clinical Theranostic Approaches, Int. J. Mol. Sci, vol.18, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01636873
Theranostics Using Antibodies and Antibody-Related Therapeutics, J. Nucl. Med, vol.58, pp.83-90, 2017. ,
Antibody Positron Emission Tomography Imaging in Anticancer Drug Development, J. Clin. Oncol, vol.33, pp.1491-1504, 2015. ,
ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.2166-2168, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01809742
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using, vol.6, pp.262-271, 2016. ,
Recommendations on the Use of 18F-FDG PET in Oncology, J. Nucl. Med, vol.49, pp.480-508, 2008. ,
, Oncology: Current Status and Perspectives. Curr. Radiol. Rep, vol.1, pp.177-190, 2013.
FDG PET/CT in cancer: Comparison of actual use with literature-based recommendations, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.695-706, 2016. ,
Understanding the standardized uptake value, its methods, and implications for usage, J. Nucl. Med, vol.45, pp.1431-1434, 2004. ,
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET. Front, vol.2, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01817854
SUV: Standard uptake or silly useless value?, J. Nucl. Med, vol.36, pp.1836-1839, 1995. ,
FDG-PET for predicting the prognosis of malignant lymphoma, Ann. Nucl. Med, vol.8, pp.187-191, 1994. ,
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma, J. Clin. Oncol, vol.23, pp.4643-4651, 2005. ,
Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma, Haematologica, vol.93, pp.471-472, 2008. ,
Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, vol.126, p.335, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01300802
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: A retrospective study from the GOELAMS group, Eur. J. Nucl. Med. Mol. Imaging, vol.37, pp.1633-1642, 2010. ,
Interest of FDG-PET in the Management of Mantle Cell Lymphoma ,
URL : https://hal.archives-ouvertes.fr/inserm-02100231
Prognostic value of FDG-PET in patients with mantle cell lymphoma: Results from the LyMa-PET Project, Haematologica, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02266351
New response evaluation criteria in solid tumours: Revised RECIST guideline (Version 1.1), Eur. J. Cancer, vol.45, pp.228-247, 2009. ,
New Guidelines to Evaluate the Response to Treatment in Solid Tumors, J. Natl. Cancer Inst, vol.92, pp.205-216, 2000. ,
RECIST 1.1-Update and Clarification: From the RECIST Committee, Eur. J. Cancer, vol.62, pp.132-137, 2016. ,
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, J. Nucl. Med, vol.50, pp.122-150, 2009. ,
Therapeutic implications of cancer stem cells, Curr. Opin. Genet. Dev, vol.14, pp.43-47, 2004. ,
The paradox of response and survival in cancer therapeutics, Blood, vol.107, pp.431-434, 2006. ,
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment versus Visual Analysis, J. Nucl. Med, vol.48, pp.1626-1632, 2007. ,
Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation, J. Clin. Oncol, vol.11, pp.2101-2111, 1993. ,
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ?SUVmax in the FDG-Avid Patients of the IMAJEM Study, Clin. Cancer Res, vol.24, pp.5219-5224, 2018. ,
Characterization of clonogenic multiple myeloma cells, Blood, vol.103, pp.2332-2336, 2004. ,
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat. Commun, vol.8, p.268, 2017. ,
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma, Int. J. Mol. Sci, 1248. ,
Dependence of FDG uptake on tumor microenvironment, Int. J. Radiat. Oncol, vol.62, pp.545-553, 2005. ,
Radiomics: Images Are More than Pictures, They Are Data, Radiology, vol.278, pp.563-577, 2016. ,
The bridge between medical imaging and personalized medicine, Nat. Rev. Clin. Oncol, vol.14, pp.749-762, 2017. ,
Radiomics in PET/CT: More Than Meets the Eye?, J. Nucl. Med, vol.58, pp.365-366, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01525677
Characterization of PET/CT images using texture analysis: The past, the present . . . any future?, Eur. J. Nucl. Med. Mol. Imaging, vol.2016, pp.1-15 ,
URL : https://hal.archives-ouvertes.fr/hal-01330349
Responsible Radiomics Research for Faster Clinical Translation, J. Nucl. Med, vol.59, pp.189-193, 2018. ,
Toward a standard for the evaluation of PET-Auto-Segmentation methods following the recommendations of AAPM task group No. 211: Requirements and implementation, vol.44, pp.4098-4111, 2017. ,
, Image biomarker standardisation initiative. arXiv 2016
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer, J. Nucl. Med, vol.52, pp.369-378, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00574272
Radiomics in PET: Principles and applications, Clin. Transl. Imaging, vol.2, pp.269-276, 2014. ,
Radiomics in Oncological PET/CT: Clinical Applications, Nucl. Med. Mol. Imaging, vol.52, pp.170-189, 2018. ,
False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review, PLoS ONE, vol.10, 2015. ,
Vulnerabilities of radiomic signature development: The need for safeguards, Radiother. Oncol, vol.130, pp.2-9, 2019. ,
External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy, Eur. J. Nucl. Med. Mol. Imaging, vol.46, pp.864-877, 2019. ,
Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of 18F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis, Radiology, vol.281, pp.270-278, 2016. ,
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC)-A prospective externally validated study, PLoS ONE, vol.13, 2018. ,
Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks, PLoS ONE, vol.10, 2015. ,
Radiomics with artificial intelligence for precision medicine in radiation therapy, J. Radiat. Res, vol.60, pp.150-157, 2019. ,
A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET, J. Nucl. Med, vol.59, pp.1321-1328, 2018. ,
Creating Robust Predictive Radiomic Models for Data from Independent Institutions Using Normalization, IEEE Trans. Radiat. Plasma Med Sci, vol.3, pp.210-215, 2019. ,
Comparison of Radiomics Models Built Through Machine Learning in a Multicentric Context with Independent Testing: Identical Data, Similar Algorithms, Different Methodologies, IEEE Trans. Radiat. Plasma Med Sci, vol.3, pp.192-200, 2019. ,
From BoW to CNN: Two Decades of Texture Representation for Texture Classification, Int. J. Comput. Vis, vol.127, pp.74-109, 2019. ,
Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.1477-1485, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01285687
Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: Prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy, Oncotarget, vol.8, pp.62606-62621, 2017. ,
A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities, Phys. Med. Boil, vol.60, pp.5471-5496, 2015. ,
Prognosis value of quantitative indices derived from initial FDG PET/CT in untreated mantle cell lymphoma patients enrolled in the Lyma trial, a LYSA study. Preliminary results, J. Nucl. Med, vol.56, p.659, 2015. ,
Quantification of intratumor heterogeneity derived from baseline FDG PET/CT in untreated mantle cell lymphoma patients enrolled in a prospective phase III trial of the LYSA group: Preliminary results, J. Nucl. Med, vol.56, p.429, 2015. ,
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma, Eur. J. Nucl. Med. Mol. Imaging, vol.2019, pp.1-10 ,
Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.768-786, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01659241